Results 161 to 170 of about 611,546 (266)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: A Promising Signal, but Not Yet the Final Word. [PDF]

Int J Heart Fail
Kim D.
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Lingual Retainer Stabilized by Modifying Archwire

Journal of Indian Orthodontic Society, 2013
Shreenivas S Astekar, Rahul Subhash Deshpande, Pravin Shankar Shetty, Arpit Dhirajlal Chanchad   +3 more
doaj   +1 more source

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U.   +14 more
europepmc   +1 more source

SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. [PDF]

JACC Asia
Morel O, Mai AT, Zühlke L, Jouven X, Marchandot B, Pressman G, Patton-Bolman C, Roffi M, Pibarot P.   +8 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014-2021. [PDF]

Ann Hematol
Suh K, Newman TV, Yang J, Haubner A, Anderson M, Triulzi DJ, Novelli EM.   +6 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Leukotriene-modifying agent chemoprophylaxis for severe influenza illness: a multi-approach study. [PDF]

Am J Epidemiol
Snyder BM, Riddell CA, Gebretsadik T, Ding T, Lee RL, Dupont WD, Ortiz JR, Pav V, Braciale TJ, Wu P, Hartert TV.   +10 more
europepmc   +1 more source